Skip to content

Trimas TRS Cumulative Cost Basis

Cumulative Cost Basis at other companies

Greif logo
GreifGEF
AptarGroup logo
AptarGroupATR
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Dow logo
DowDOW
Dover logo
DoverDOV
Kulicke & Soffa Industries logo
Kulicke & Soffa IndustriesKLIC

Other financials

Income statement

See full
Revenue$168.3M+10.4%
Gross profit$36.9M+12.3%
Operating income$6.9M-3.6%
Net income$800.8M+6,348%
EPS (diluted)$21.40+7,033%

Balance sheet

See full
Cash & equivalents$1.3B+3,904%
Total debt$439.9M-9.2%
Total equity$1.4B+111%
Total assets$2.3B+64.8%

Cash flow

See full
Operating cash flow-$19.4M-311%
CapEx$5.2M-59.7%
Free cash flow-$24.6M-556%

Valuation

See full
Market cap$1.56B+41.9%
Enterprise value$692.33M-65.6%
P/E1.7×-33.2×
P/S2.4×+0.6×

Profitability

See full
Gross margin-0.1%-2.1pp
Operating margin8%-1.0pp
Net margin137.3%+132pp
FCF margin7.3%+3.1pp

Returns & leverage

See full
Return on equity85.1%+80.4pp
Debt / equity0.3×-0.4×
Current ratio4.9×+2.0×

Where this comes from

Reported directly by Trimas in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Trimas’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trimas's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trimas's cumulative cost basis?
Trimas (TRS) reported cumulative cost basis of $522.93M in Q1 2026.
How has Trimas's cumulative cost basis changed year-over-year?
Trimas's cumulative cost basis decreased by 19.7% year-over-year, from $651.56M to $522.93M.
What is the long-term trend for Trimas's cumulative cost basis?
Over 5 years (2020 to 2025), Trimas's cumulative cost basis has grown at a 1.1% compound annual growth rate (CAGR), from $496.02M to $524.84M.